Two out of the three major indices are trading up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 28 points (0.2%) at 17,783 as of Friday, Oct. 30, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,543 issues advancing vs. 1,349 declining with 225 unchanged.

The Drugs industry currently sits down 1.0% versus the S&P 500, which is unchanged. On the negative front, top decliners within the industry include

Valeant Pharmaceuticals International

(

VRX

), down 11.0%,

Pfizer

(

PFE

), down 1.8% and

Bristol-Myers Squibb Company

(

BMY

), down 1.1%. A company within the industry that increased today was

GlaxoSmithKline

(

GSK

), up 1.4%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3.

Mylan

(

MYL

) is one of the companies pushing the Drugs industry lower today. As of noon trading, Mylan is down $1.66 (-3.6%) to $44.12 on heavy volume. Thus far, 7.7 million shares of Mylan exchanged hands as compared to its average daily volume of 8.2 million shares. The stock has ranged in price between $43.43-$46.05 after having opened the day at $45.49 as compared to the previous trading day's close of $45.78.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Mylan N.V., through its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. Mylan has a market cap of $21.7 billion and is part of the health care sector. Shares are down 18.8% year-to-date as of the close of trading on Thursday. Currently there are 4 analysts that rate Mylan a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates

Mylan

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, reasonable valuation levels, compelling growth in net income and expanding profit margins. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Mylan Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreet Recommends

2. As of noon trading,

Amgen

(

AMGN

) is down $1.33 (-0.8%) to $159.25 on average volume. Thus far, 2.0 million shares of Amgen exchanged hands as compared to its average daily volume of 4.2 million shares. The stock has ranged in price between $158.65-$162.00 after having opened the day at $161.06 as compared to the previous trading day's close of $160.58.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. Amgen has a market cap of $122.8 billion and is part of the health care sector. Shares are up 0.8% year-to-date as of the close of trading on Thursday. Currently there are 6 analysts that rate Amgen a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates

Amgen

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, reasonable valuation levels and increase in stock price during the past year. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full

Amgen Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Celgene

(

CELG

) is down $1.96 (-1.6%) to $122.97 on average volume. Thus far, 2.4 million shares of Celgene exchanged hands as compared to its average daily volume of 5.4 million shares. The stock has ranged in price between $122.10-$125.99 after having opened the day at $124.80 as compared to the previous trading day's close of $124.93.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. Celgene has a market cap of $99.4 billion and is part of the health care sector. Shares are up 11.7% year-to-date as of the close of trading on Thursday. Currently there are 12 analysts that rate Celgene a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Celgene

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, reasonable valuation levels, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Celgene Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).